- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03767348
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
August 1, 2023 updated by: Replimune Inc.
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
RP1 is a genetically modified herpes simplex type 1 virus that is designed to directly destroy tumors and to generate an anti-tumor immune response.
This is a Phase 1/2, open label, multicenter, dose escalation and expansion, first-in-human (FIH) clinical study to evaluate the safety and tolerability, biodistribution, shedding, and preliminary efficacy of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors.
The study will include a dose escalation phase for single agent RP1, an expansion phase with a combination of RP1 and nivolumab and a Phase 2 portion in specified tumor types for the combination therapy.
Study Type
Interventional
Enrollment (Estimated)
340
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Clinical Trials at Replimune
- Phone Number: 1-781-222-9570
- Email: Clinicaltrials@replimune.com
Study Locations
-
-
-
Besançon, France, 25000
- Recruiting
- CHU Besançon - Hôpital Jean Minjoz
-
Principal Investigator:
- Nardin Charlee, MD
-
Bordeaux, France, 33076
- Recruiting
- Institut Bergonié
-
Principal Investigator:
- Antoine Italiano, MD
-
Dijon, France, 21079
- Recruiting
- CHU Dijon
-
Principal Investigator:
- Sophie Dalac-Rat, MD
-
Lyon, France, 69373
- Recruiting
- Centre Léon Bérard Lyon
-
Contact:
- Mona AMINI-ADLE, MD
-
Principal Investigator:
- Mona AMINI-ADLE, MD
-
Marseille, France, 13005
- Recruiting
- Service de Dermatologie et Cancerologie Cutanee Hopital de la Timone
-
Principal Investigator:
- Caroline Gaudy, MD
-
Nice, France, 06200
- Recruiting
- CHU de Nice Hôpital l'Archet
-
Principal Investigator:
- Henri MONTAUDIE, MD
-
Paris, France, 75010
- Recruiting
- Hôpital Saint Louis APHP
-
Principal Investigator:
- Céleste Lebbe, MD
-
Villejuif, France, 94800
- Recruiting
- Institut Gustave Roussy
-
Principal Investigator:
- Judith Michels, MD
-
-
-
-
-
Berlin, Germany, 12203
- Recruiting
- Charité (Campus Benjamin Franklin)
-
Principal Investigator:
- Sebastian Ochsenreither, MD
-
Essen, Germany, 45147
- Recruiting
- University Hospital Essen, Klinik für Dermatologie
-
Principal Investigator:
- Dirk Schadendorf, MD
-
Kiel, Germany, 24105
- Recruiting
- University of Kiel (UKSH), Dep. of Dermatology
-
Principal Investigator:
- Katharina Kahler, MD
-
Marburg, Germany, 35043
- Recruiting
- Uniklinik Marburg
-
Principal Investigator:
- Martin Gschnell, MD
-
-
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitari Vall d'Hebron
-
Principal Investigator:
- Eva Couselo Munoz, MD
-
Barcelona, Spain, 08036
- Recruiting
- Hospital Clinic Barcelona
-
Principal Investigator:
- Ana Arance Fernandez, MD
-
Barcelona, Spain, 08908
- Recruiting
- Institut Catala D'Oncologia - Hospital Duran I
-
Principal Investigator:
- Juan Liberal Martin, MD
-
Madrid, Spain, 28027
- Recruiting
- Clinica Universidad de Navarra (Madrid)
-
Principal Investigator:
- Miguel Fernández de Sanmamed
-
Murcia, Spain, 30120
- Recruiting
- Hospital Universitario Virgen de la Arrixaca
-
Principal Investigator:
- Pablo Cerezuela, MD
-
Pamplona, Spain, 31008
- Recruiting
- Clinica Universitaria de Navarra
-
Principal Investigator:
- Miguel Gutiérrez Sanmamed, MD
-
Sevilla, Spain, 41013
- Recruiting
- Hospital Universitario Virgen Del Rocio
-
Principal Investigator:
- Ana Gill, MD
-
Valencia, Spain, 46014
- Recruiting
- Hospital General Universitario de Valencia
-
Principal Investigator:
- Alfonso Jaime Berrocal, MD
-
-
-
-
-
London, United Kingdom
- Recruiting
- Royal Marsden Hospital
-
Principal Investigator:
- Kevin Harrington, BSc FRCP PhD
-
Southampton, United Kingdom, SO16 6YD
- Recruiting
- Southampton General Hospital
-
Principal Investigator:
- Ioannis Karydis, MD
-
-
England
-
Leeds, England, United Kingdom, LS97TF
- Recruiting
- University of Leeds- Teaching Hospital
-
Principal Investigator:
- Adel Samson, MD
-
-
Oxfordshire
-
Oxford, Oxfordshire, United Kingdom
- Recruiting
- Oxford University Hospitals NHS Trust
-
Principal Investigator:
- Mark R Middleton, MD,PhD,FRCP
-
-
Scotland
-
Glasgow, Scotland, United Kingdom, G12 0YN
- Recruiting
- Beatson West of Scotland Cancer Center
-
Principal Investigator:
- Patricia Roxburgh, MD
-
-
Wirral
-
Bebington, Wirral, United Kingdom, CH634JY
- Recruiting
- The Clatterbridge Cancer Centre NHS Foundation Trust
-
Principal Investigator:
- Joseph Sacco, MRCP, PhD
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Active, not recruiting
- University of Birmingham Alabama
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Recruiting
- Banner MD Anderson Cancer Center
-
Principal Investigator:
- Jiaxin Niu, MD
-
Contact:
- Jenesse Moffett
-
Phoenix, Arizona, United States, 85054
- Recruiting
- Mayo Clinic
-
Principal Investigator:
- Mahesh Seetharam, MD
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Recruiting
- CARTI Cancer Center
-
Principal Investigator:
- Issam Makhoul, MD
-
-
California
-
La Jolla, California, United States, 92093
- Active, not recruiting
- UC San Diego
-
Los Angeles, California, United States, 90033
- Recruiting
- University of Southern California
-
Contact:
- Gino In, MD
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA
-
Contact:
- Danell Johnson
-
Principal Investigator:
- Bartosz Chmielowski, MD
-
Orange, California, United States, 92868
- Recruiting
- University of California, Irvine
-
Principal Investigator:
- John Fruehauf, MD
-
San Francisco, California, United States, 94115
- Recruiting
- University of California- San Francisco
-
Principal Investigator:
- Katy Tsai, MD
-
Contact:
- Melissa Chow
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- Sylvester Comprehensive Cancer Center- University of Miami
-
Principal Investigator:
- Estelamari Rodriguez, MD
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa-Cancer Center Research
-
Contact:
- Mariel McKay
-
Principal Investigator:
- Mohammed Milhem, MBBS
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Recruiting
- James Graham Brown Cancer Center- University of Louisville
-
Contact:
- Stacy Baum
-
Principal Investigator:
- Jason Chesney, MD
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Principal Investigator:
- Robert McWilliams, MD
-
-
New Jersey
-
Morristown, New Jersey, United States, 07960
- Recruiting
- Atlantic Health System
-
Contact:
- Eric Whitman, MD
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Weill Cornell Medical College
-
Principal Investigator:
- Anna Pavlick, DO
-
New York, New York, United States, 10016
- Active, not recruiting
- New York University Clinical Cancer Center
-
Rochester, New York, United States, 14642
- Recruiting
- University of Rochester Medical Center
-
Contact:
- Delaney Dretto
-
Contact:
- Janice Cifelli
-
Principal Investigator:
- Rachael Turner, MD
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke Cancer Center
-
Contact:
- Georgia Beasley, MD
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Recruiting
- University of Cincinnati Medical Center
-
Principal Investigator:
- Trisha Wise-Draper, MD
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Active, not recruiting
- Providence Portland Medical Center
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- MUSC Health
-
Contact:
- John Kaczmar, MD
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Recruiting
- West Cancer Center
-
Contact:
- Alisa Harber
-
Principal Investigator:
- Ari VanderWalde, MD
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas MD Anderson Cancer Center
-
Principal Investigator:
- Michael Wong, MD
-
-
Utah
-
Murray, Utah, United States, 84107
- Recruiting
- Eccles Outpatient Care Center- Oncology Clinical Trials
-
Contact:
- Tawnya Bowles
-
Principal Investigator:
- Tawnya Bowles, MD
-
Saint George, Utah, United States, 84790
- Recruiting
- Intermountain Cancer Center- Saint George Cancer Center
-
Contact:
- Angi Cox
-
Principal Investigator:
- Terence Rhodes, MD
-
-
Washington
-
Seattle, Washington, United States, 98109
- Recruiting
- Seattle Cancer Care Alliance- University of Washington
-
Contact:
- Katie Kim
-
Principal Investigator:
- Evan Hall, MD
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Active, not recruiting
- University of Wisconsin-Carbone Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
- At least one measurable and injectable lesion
- Have provided a former tumor pathology specimen or be willing to supply a new tumor sample from a biopsy
- Have a predicted life expectancy of ≥ 3 months
- Measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria
- Subjects with MSI-H or dMMR tumors: has diagnosis of MSI-H or metatstatic dMMR tumor (according to protocol definition) who has progressed on prior anti-PD1/PD-L1 therapy.
- Subjects with NMSC: has diagnosis of locally advanced or metastatic NMSC that are not considered treatable by surgery including basal cell carcinoma, cutaneous squamous cell carcinoma, basosquamous carcinoma, Merkel cell carcinoma and other non-melanoma skin cancers (per protocol). Patients must have received 8 weeks of anti-PD1/PD-L1 as their last line of therapy and progressed while on treatment.
- Subjects with anti-PD1 failed cutaneous melanoma: has confirmed progressive disease while on anti-PD1 treatment for at least 8 weeks and documented BRAF mutation status
- Subjects with anti-PD1 failed NSCLC: must have failed prior treatment, including PD1/PD-L1 directed therapy administered either as monotherapy or in combination with platinum-based chemotherapy or anti-CTLA-4. The most recent treatment given must have included an anti-PD1/PD-L1 directed therapy with radiologic disease progression on or after treatment.
Exclusion Criteria:
- Prior treatment with an oncolytic therapy
- History of viral infections according to the protocol
- Prior complications with herpes infections
- Chronic use of anti-virals
- Uncontrolled/untreated brain metastasis
- History of interstitial lung disease
- History of non-infectious pneumonitis
- History of clinically significant cardiovascular disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose escalation of RP1 by intratumoral (IT) injection in superficial tumors
Dose escalation of RP1 alone in 3 cohorts with IT injections in superficial tumors
|
Genetically modified herpes simplex type 1 virus
|
Experimental: Dose escalation of RP1 by intratumoral (IT) injection in deep/visceral tumors
Dose escalation of RP1 alone in 3 cohorts with IT injections in deep/visceral tumors
|
Genetically modified herpes simplex type 1 virus
|
Experimental: Dose expansion of RP1 and nivolumab (IV) in superficial tumors
Doses of RP1 (IT) in superficial tumors with nivolumab (IV)
|
Genetically modified herpes simplex type 1 virus
anti-PD-1 monoclonal antibody
Other Names:
|
Experimental: Dose expansion of RP1 and nivolumab (IV) in deep/visceral tumors
Doses of RP1 (IT) in deep/visceral tumors with nivolumab (IV)
|
Genetically modified herpes simplex type 1 virus
anti-PD-1 monoclonal antibody
Other Names:
|
Experimental: RP1 (IT) and nivolumab (IV) in melanoma
Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with melanoma
|
Genetically modified herpes simplex type 1 virus
anti-PD-1 monoclonal antibody
Other Names:
|
Experimental: RP1 (IT) and nivolumab (IV) in MSI-H/dMMR solid tumors
Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with MSI-H or dMMR solid tumors
|
Genetically modified herpes simplex type 1 virus
anti-PD-1 monoclonal antibody
Other Names:
|
Experimental: RP1 (IT) and nivolumab (IV) in NMSC
Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non-melanoma skin cancer
|
Genetically modified herpes simplex type 1 virus
anti-PD-1 monoclonal antibody
Other Names:
|
Experimental: RP1(IT) and nivolumab (IV) in anti-PD1 Failed Cutaneous Melanoma
Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with cutaneous melanoma who have been previously treated with anti-PD1 therapy
|
Genetically modified herpes simplex type 1 virus
anti-PD-1 monoclonal antibody
Other Names:
|
Experimental: RP1(IT) and nivolumab (IV) in anti-PD1/PD-L1 Failed NMSC
Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non-melanoma skin cancer who have been previously treated with anti-PD1/PD-L1 therapy
|
Genetically modified herpes simplex type 1 virus
anti-PD-1 monoclonal antibody
Other Names:
|
Experimental: RP1(IT) and nivolumab (IV) in anti-PD1/PD-L1 Failed NSCLC
Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non small cell lung cancer who have been previously treated with anti-PD1/PD-L1 therapy
|
Genetically modified herpes simplex type 1 virus
anti-PD-1 monoclonal antibody
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of adverse events (AEs)
Time Frame: 26 months
|
Percentage of subjects with adverse events (AEs)
|
26 months
|
Percentage of serious adverse events (SAEs)
Time Frame: 26 months
|
Percentage of subjects with serious adverse events (SAEs)
|
26 months
|
Percentage of dose limiting toxicities (DLTs)
Time Frame: 26 months
|
Percentage of subjects with dose limiting toxicities (DLTs)
|
26 months
|
Percentage of overall response rate (ORR)
Time Frame: 26 months
|
Percentage of overall response rate (ORR) for all participants
|
26 months
|
Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RP1
Time Frame: 20 weeks
|
Assess the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RP1 based on the safety and response data collected during Phase 1 Escalation
|
20 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of biologic activity
Time Frame: 20 weeks
|
Percentage of subjects with biological activity determined by tumor biopsies and biomarker data
|
20 weeks
|
Percentage subjects with detectable RP1
Time Frame: 20 weeks
|
Data gathered from blood, urine, swabs of injection site, dressings, and oral mucosa to determine the shedding and biodistribution of RP1
|
20 weeks
|
Percentage of complete response (CR)
Time Frame: 26 months
|
Percentage of subjects with a complete response (CR)
|
26 months
|
Median duration of response
Time Frame: 26 months
|
Median duration of response of subjects
|
26 months
|
Median progression-free survival
Time Frame: 26 months
|
Median duration of progression-free survival of subjects
|
26 months
|
Median overall survival
Time Frame: 26 months
|
Median overall survival rate of subjects
|
26 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Jeannie Hou, MD, Replimune Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 20, 2017
Primary Completion (Estimated)
November 1, 2024
Study Completion (Estimated)
November 1, 2024
Study Registration Dates
First Submitted
December 5, 2018
First Submitted That Met QC Criteria
December 5, 2018
First Posted (Actual)
December 6, 2018
Study Record Updates
Last Update Posted (Actual)
August 2, 2023
Last Update Submitted That Met QC Criteria
August 1, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Genomic Instability
- Melanoma
- Skin Neoplasms
- Microsatellite Instability
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
Other Study ID Numbers
- RPL-001-16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on RP1
-
Sherrif IbrahimRecruitingSquamous Cell Carcinoma | RP1United States
-
Replimune Inc.RecruitingMelanoma | Merkel Cell Carcinoma | Basal Cell Carcinoma | Cutaneous Squamous Cell CarcinomaUnited States
-
Yana NajjarReplimune Inc.Recruiting
-
Birgitte Klug AlbertsenERYtech PharmaCompletedAcute Lymphoblastic LeukemiaNorway, Finland, Sweden, Lithuania, Denmark, Estonia
-
Replimune Inc.Regeneron PharmaceuticalsActive, not recruitingCutaneous Squamous Cell Carcinoma | Advanced Cutaneous Squamous Cell Carcinoma | Metastatic Cutaneous Squamous Cell CarcinomaSpain, United States, France, Australia, Germany, Canada, Greece, Bulgaria, Italy, Poland
-
Institut CurieRoche Pharma AG; Replimune Inc.Not yet recruitingTriple Negative Breast NeoplasmsFrance
-
Nippon Kayaku Co., Ltd.CompletedWegener's GranulomatosisUnited Kingdom, Germany, Sweden, Czech Republic, Denmark, Netherlands
-
Replimune Inc.Not yet recruiting